| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
PEGs
m-PEG4-PFP ester does not target a biological receptor; it is a chemical linker used in the synthesis of PROTACs. The PFP ester group reacts efficiently with primary amines (-NH2) on amino-containing molecules (e.g., E3 ligase ligands or target protein-binding ligands) to form stable amide bonds. The PEG4 spacer provides flexibility and hydrophilicity. |
|---|---|
| ln Vitro |
A linker separates the two ligands that make up PROTACs; one ligand is for an E3 ubiquitin ligase, and the other is for the target protein. Target proteins are selectively degraded by PROTACs by taking advantage of the intracellular ubiquitin-proteasome system[1].
Not applicable. As a PROTAC linker, m-PEG4-PFP ester has no biological activity on its own. Its utility is assessed when incorporated into a complete PROTAC molecule by enabling conjugation between a target-binding moiety and an E3 ubiquitin ligase-binding moiety. The PEG4 linker length (approximately 4 ethylene glycol units) provides optimal spacing for ternary complex formation. |
| ln Vivo |
Not applicable. m-PEG4-PFP ester is a chemical reagent used for PROTAC synthesis, not a therapeutic agent. It is not administered to animals as a free compound. PROTACs assembled using m-PEG4-PFP ester have been evaluated in vivo for target protein degradation and anti-tumor efficacy, but no specific in vivo data is provided for the linker itself.
|
| Enzyme Assay |
A standard conjugation protocol involves dissolving m-PEG4-PFP ester (1 equivalent, e.g., 1-10 micromol) in anhydrous DMF or DMSO. An amine-containing molecule (e.g., a ligand for an E3 ligase such as pomalidomide-NH2 or VHL ligand, 0.9-1.2 equivalents) and a base (e.g., DIPEA or TEA, 2-5 equivalents) are added. The reaction is stirred at room temperature for 2-24 hours. Progress is monitored by TLC or HPLC-MS. The product is purified by preparative HPLC or column chromatography.
|
| Cell Assay |
Not applicable. m-PEG4-PFP ester is not used directly in cell-based assays. The final PROTAC compound synthesized using this linker is evaluated in cellular degradation assays. A typical cellular protocol for PROTAC activity involves treating target-expressing cells (e.g., cancer cell lines) with the PROTAC (0.001-10 microM) for 4-24 hours, followed by Western blotting to quantify degradation of the target protein.
|
| Animal Protocol |
Not applicable. The in vivo efficacy of a PROTAC synthesized using m-PEG4-PFP ester would be assessed in xenograft mouse models. Typical protocols involve administering the PROTAC (e.g., 10-100 mg/kg) by intraperitoneal or intravenous injection in tumor-bearing mice, monitoring tumor volume for 2-4 weeks, and analyzing target protein levels in tumor tissues by immunohistochemistry or Western blot at study endpoint.
|
| ADME/Pharmacokinetics |
m-PEG4-PFP ester has a molecular weight of 402.31 (C16H19F5O6) and CAS number 2952895-31-5. The PFP ester is a highly reactive activated ester that hydrolyzes rapidly in aqueous environments. For storage, the compound should be kept in a dry, anhydrous environment at -20degC to prevent hydrolysis. It is soluble in anhydrous DMF, DMSO, and dichloromethane.
|
| Toxicity/Toxicokinetics |
m-PEG4-PFP ester is a reactive chemical that can cause skin and eye irritation. The PFP ester group is susceptible to hydrolysis, releasing pentafluorophenol, which is an irritant. Standard laboratory safety precautions (gloves, goggles, fume hood) should be used when handling this compound. No additional toxicological data is provided.
|
| References | |
| Additional Infomation |
m-PEG4-PFP ester is a research-grade PEG-based PROTAC linker. It is used for the synthesis of PROTAC degraders, a cutting-edge technology for targeted protein degradation in cancer and other diseases. The PFP ester enables efficient, one-step conjugation to amine-functionalized molecules. This product is strictly for laboratory research in chemical biology and drug discovery.
|
| Molecular Formula |
C16H19F5O6
|
|---|---|
| Molecular Weight |
402.31
|
| Exact Mass |
402.11
|
| CAS # |
2952895-31-5
|
| PubChem CID |
146025871
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.316±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)
|
| Boiling Point |
415.4±45.0 °C(predicted)
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
27
|
| Complexity |
403
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COCCOCCOCCOCCC(=O)OC1=C(C(=C(C(=C1F)F)F)F)F
|
| InChi Key |
SVJYYIVPHFUIOX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H19F5O6/c1-23-4-5-25-8-9-26-7-6-24-3-2-10(22)27-16-14(20)12(18)11(17)13(19)15(16)21/h2-9H2,1H3
|
| Chemical Name |
(2,3,4,5,6-pentafluorophenyl) 3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4856 mL | 12.4282 mL | 24.8565 mL | |
| 5 mM | 0.4971 mL | 2.4856 mL | 4.9713 mL | |
| 10 mM | 0.2486 mL | 1.2428 mL | 2.4856 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
